Background: Asia is the largest, most populous and most heterogeneous continent in the world. The number of patients with end-stage renal disease is growing rapidly in Asia. Summary: A fully informed report on the status of dialysis therapies including hemodialysis (HD) is limited by the lack of systematic registries. Available data suggest remarkable heterogeneities, with some countries like Taiwan, Japan and Korea exhibiting well-established HD systems, high prevalence and universal access to all patients, while low- and low-middle income countries are unable to provide HD to eligible patients because of high cost and poor healthcare systems. Many Asian countries have unregulated dialysis units, with poor standards of delivery, quality control and outcome reporting. This leads to high mortality due to preventable complications like infections. Modeling data suggest that at least 2.9 million people need dialysis in Asia, which represents a gap in availability of dialysis to the tune of -66%. The population is projected to grow rapidly in the coming years. Several countries are expanding access to HD. Innovative modifications in dialysis practice are being made to optimize outcomes. It is important to develop robust systems of documentation and outcome reporting to evaluate the effects of such changes. HD needs to develop in conjunction with effective preventive programs and improvement of health systems. Key Messages: The practice of HD in Asia is growing and evolving. Rapid expansion will improve the currently dismal access to care for large sections of the population. Quality issues need to be addressed if the full benefit of this therapy is to reach the population. Developed countries of Asia can provide substantial messages to developing economies. HD programs must develop in conjunction with prevention efforts. Facts from East and West: (1) While developed Western and Asian countries provide end-stage renal disease patients full access to HD, healthcare systems from South and South-East Asia can offer access to HD only to a limited fraction of the patients in need. Even though the annual costs of HD are much lower in less developed countries (for instance 30 times lower in India compared to the US), patients often cannot afford costs not covered by health insurance. (2) The recommended dialysis pattern in the West is at least three sessions weekly with high-flux dialyzers. Studies from Shanghai and Taiwan might however indicate a benefit of twice versus thrice weekly sessions. In less developed Asian countries, a twice weekly pattern is common, sometimes with dialyzer reuse and inadequate water treatment. A majority of patients decrease session frequency or discontinue the program due to financial constraint. (3) As convective therapies are gaining popularity in Europe, penetration in Asia is low and limited by costs. (4) In Asian countries, in particular in the South and South-East, hepatitis and tuberculosis infections in HD patients are higher than in the West and substantially increase mortality. (5) Progress has recently been made in countries like Thailand and Brunei to provide universal HD access to all patients in need. Nevertheless, well-trained personnel, reliable registries and better patient follow-up would improve outcomes in low-income Asian countries.

Keywords:
Economics, End-stage renal disease, Hemodialysis, Cost of care, Asia
1.
Asia Population 2015 - World Population Review. Available at http://worldpopulationreview.com/continents/asia-population/ (accessed October 2, 2015).
2.
Jones CA, Krolewski AS, Rogus J, et al: Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause? Kidney Int 2005;67:1684-1691.
3.
Meguid El Nahas A, Bello AK: Chronic kidney disease: the global challenge. Lancet 2005;365:331-340.
4.
Gooneratne IK, Ranaweera AK, Liyanarachchi NP, et al: Epidemiology of chronic kidney disease in a Sri Lankan population. Int J Diabetes Dev Ctries 2008;28:60-64.
5.
Rajapurkar MM, John GT, Kirpalani AL, et al: What do we know about chronic kidney disease in India: first report of the Indian CKD registry. BMC Nephrol 2012;13:10.
6.
Lozano R, Naghavi M, Foreman K, et al: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-2128.
7.
Chugh KS, Jha V, Chugh S: Economics of dialysis and renal transplantation in the developing world. Transplant Proc 1999;31:3275-3277.
8.
Jha V: End-stage renal care in developing countries: the India experience. Ren Fail 2004;26:201-208.
9.
Jha V: Current status of chronic kidney disease care in southeast Asia. Semin Nephrol 2009;29:487-496.
10.
Lee G: End-stage renal disease in the Asian-Pacific region. Semin Nephrol 2003;23:107-114.
11.
Wu AY, Kong NC, de Leon FA, et al: An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 2005;48:17-26.
12.
Gross A: India's dialysis market. Published on July 10, 2013 in Medical Device Daily by Pacific Bridge Medical. Available at http://www.pacificbridgemedical.com/publications/high-rates-of-chronic-kidney-disease-lead-to-medtech-opportunities-in-india/ (accessed October 2, 2015).
13.
Agarwal SK, Dash SC, Irshad M, et al: Prevalence of chronic renal failure in adults in Delhi, India. Nephrol Dial Transplant 2005;20:1638-1642.
14.
Jha V, Garcia-Garcia G, Iseki K, et al: Chronic kidney disease: global dimension and perspectives. Lancet 2013;382:260-272.
15.
Jha V: Current status of end-stage renal disease care in India and Pakistan. Kidney Int Suppl (2011) 2013;3:157-160.
16.
Singh A, Prakash G: Public-private partnerships in health services delivery. Public Manage Rev 2010;12:829-856.
17.
Chakraborty D: The private sector's role in achieving universal health coverage in India. Available at http://www.emhn.org/sites/default/files/Chakraborty_PPPs_EMHN.pdf.
18.
De Vecchi AF, Dratwa M, Wiedemann ME: Healthcare systems and end-stage renal disease (ESRD) therapies - an international review: costs and reimbursement/funding of ESRD therapies. Nephrol Dial Transplant 1999;14(suppl 6):31-41.
19.
Ramachandran R, Jha V: Kidney transplantation is associated with catastrophic out of pocket expenditure in India. PLoS One 2013;8:e67812.
20.
Jha V, Chugh KS: The practice of dialysis in the developing countries. Hemodial Int 2003;7:239-249.
21.
Liu FX, Rutherford P, Smoyer-Tomic K, et al: A global overview of renal registries: a systematic review. BMC Nephrol 2015;16:31.
22.
Liyanage T, Ninomiya T, Jha V, et al: Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 2015;385:1975-1982.
23.
Tantivess S, Werayingyong P, Chuengsaman P, et al: Universal coverage of renal dialysis in Thailand: promise, progress, and prospects. BMJ 2013;346:f462.
24.
Khanna U: The economics of dialysis in India. Indian J Nephrol 2009;19:1-4.
25.
Central Intelligence Agency: The World Factbook. South Asia: India. Available at https://www.cia.gov/library/publications/the-world-factbook/geos/in.html (accessed October 2, 2015).
26.
Mani MK: The management of end-stage renal disease in India. Artif Organs 1998;22:182-186.
27.
Morad Z, Lee DG, Lim YN, et al: Peritoneal dialysis in Malaysia. Perit Dial Int 2005;25:426-431.
28.
Parameswaran S, Geda SB, Rathi M, et al: Referral pattern of patients with end-stage renal disease at a public sector hospital and its impact on outcome. Natl Med J India 2011;24:208-213.
29.
Rao M, Juneja R, Shirly RB, et al: Haemodialysis for end-stage renal disease in Southern India - a perspective from a tertiary referral care centre. Nephrol Dial Transplant 1998; 13:2494-2500.
30.
Chugh KS, Jha V: Differences in the care of ESRD patients worldwide: required resources and future outlook. Kidney Int Suppl 1995;50:S7-S13.
31.
Lin YF, Huang JW, Wu MS, et al: Comparison of residual renal function in patients undergoing twice-weekly versus three-times-weekly haemodialysis. Nephrology 2009;14:59-64.
32.
Zhang M, Wang M, Li H, et al: Association of initial twice-weekly hemodialysis treatment with preservation of residual kidney function in ESRD patients. Am J Nephrol 2014;40:140-150.
33.
Kalantar-Zadeh K, Unruh M, Zager PG, et al: Twice-weekly and incremental hemodialysis treatment for initiation of kidney replacement therapy. Am J Kidney Dis 2014;64:181-186.
35.
Dhrolia MF, Nasir K, Imtiaz S, et al: Dialyzer reuse: justified cost saving for South Asian region. J Coll Physicians Surg Pak 2014;24:591-596.
36.
Naramura T, Hyodo T, Kokubo K, et al: Dialysis and quality of dialysate in Southeast Asian developing countries. Nephron Extra 2014;4:64-69.
37.
Wilkinson E, Randhawa G: An examination of concordance and cultural competency in the diabetes care pathway: South Asians living in the United Kingdom. Indian J Nephrol 2012;22:424-430.
38.
Wilkinson E, Randhawa G, Farrington K, et al: Lack of awareness of kidney complications despite familiarity with diabetes: a multi-ethnic qualitative study. J Ren Care 2011;37:2-11.
39.
Jha V, Chugh S, Chugh KS: Infections in dialysis and transplant patients in tropical countries. Kidney Int 2000;57:85-93.
40.
Gomez AT, Kiberd BA, Royston JP, et al: Comorbidity burden at dialysis initiation and mortality: a cohort study. Can J Kidney Health Dis 2015;2:34.
41.
Laupland KB, Gregson DB, Zygun DA, et al: Severe bloodstream infections: a population-based assessment. Crit Care Med 2004;32:992-997.
42.
Kosa SD, Lok CE: The economics of hemodialysis catheter-related infection prophylaxis. Semin Dial 2013;26:482-493.
43.
Duong CM, Olszyna DP, McLaws ML: Hepatitis B and C virus infections among patients with end stage renal disease in a low-resourced hemodialysis center in Vietnam: a cross-sectional study. BMC Public Health 2015;15:192.
44.
Johnson DW, Dent H, Yao Q, et al: Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transplant 2009;24:1598-1603.
45.
Yu ML, Chuang WL: Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009;24:336-345.
46.
Agarwal SK: Hemodialysis of patients with HCV infection: isolation has a definite role. Nephron Clin Pract 2011;117:c328-c332.
47.
Potsangbam G, Yadav A, Chandel N, et al: Challenges in containing the burden of hepatitis B infection in dialysis and transplant patients in India. Nephrology 2011;16:383-388.
48.
Fabrizi F, Messa P: Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population? Expert Rev Clin Pharmacol 2015;8:785-793.
49.
Goodchild M, Sahu S, Wares F, et al: A cost-benefit analysis of scaling up tuberculosis control in India. Int J Tuberc Lung Dis 2011;15:358-362.
50.
World Health Organization: Global tuberculosis report 2014. Geneva, WHO, 2014.
51.
Costa JM, Meyers AM, Botha JR, et al: Mycobacterial infections in recipients of kidney allografts. A seventeen-year experience. Acta Med Port 1988;1:51-57.
52.
Singh N, Paterson DL: Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998;27:1266-1277.
53.
Pai M, Denkinger CM, Kik SV, et al: Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev 2014;27:3-20.
54.
Shankar MS, Aravindan AN, Sohal PM, et al: The prevalence of tuberculin sensitivity and anergy in chronic renal failure in an endemic area: tuberculin test and the risk of post-transplant tuberculosis. Nephrol Dial Transplant 2005;20:2720-2724.
55.
Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, et al: Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 2011;80:88-92.
56.
Jiang JL, Ren W, Song J, et al: The impact of short daily hemodialysis on anemia and the quality of life in Chinese patients. Braz J Med Biol Res 2013;46:629-633.
57.
Pisoni RL, Greenwood RN: Selected lessons learned from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Contrib Nephrol 2005;149:58-68.
58.
Kim H, Kim KH, Park K, et al: A population-based approach indicates an overall higher patient mortality with peritoneal dialysis compared to hemodialysis in Korea. Kidney Int 2014;86:991-1000.
59.
Goodkin DA, Bragg-Gresham JL, Koenig KG, et al: Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003;14:3270-3277.
60.
Masakane I: High-quality dialysis: a lesson from the Japanese experience. Effects of membrane material on nutritional status and dialysis-related symptoms. Clin Kidney J 2010;3:i28-i35.
61.
Wu MS, Wu IW, Hsu KH: Survival analysis of Taiwan Renal Registry Data System (TWRDS) 2000-2009. Acta Nephrologica 2012;26:104-108.
62.
Malaysian Society of Nephrology: 21th Report of the Malaysian Dialysis and Transplant Registry 2013. Available at http://www.msn.org.my/fwbPagePublic.jsp?fwbPageId=pMdtr2013 (accessed October 2, 2015).
63.
Park J, Jin DC, Molnar MZ, et al: Mortality predictability of body size and muscle mass surrogates in Asian vs white and African American hemodialysis patients. Mayo Clin Proc 2013;88:479-486.
64.
Abraham G, Jayaseelan T, Matthew M, et al: Resource settings have a major influence on the outcome of maintenance hemodialysis patients in South India. Hemodial Int 2010;14:211-217.
65.
Jha V, John O, Joshi R, et al: Dialysis outcomes in India: a pilot study. Nephrology 2015;20:329-334.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.